Subject characteristics
| Analysis population, n=19 261 | |
| Age, years | |
| Mean±SD | 43.2±9.4 |
| n (%) | |
| 18–19 | 33 (0.2) |
| 20–29 | 1572 (8.2) |
| 30–39 | 4932 (25.6) |
| 40–49 | 7593 (39.4) |
| 50–59 | 4421 (23.0) |
| 60–69 | 681 (3.5) |
| ≥70 | 29 (0.2) |
| Sex, n (%) | |
| Male | 18 924 (98.3) |
| Female | 337 (1.7) |
| eGFR, mL/min/1.73 m2* | |
| Mean±SD | 75.59±14.15 |
| n (%) | |
| ≥90 | 2736 (14.2) |
| ≥60,<90 | 14 339 (74.4) |
| ≥30,<60 | 2150 (11.2) |
| ≥15,<30 | 22 (0.1) |
| <15 | 14 (<0.1) |
| ≥60 | 17 075 (88.7) |
| <60 | 2186 (11.3) |
| sUA, mg/dL | |
| Mean±SD | 8.47±0.53 |
| n (%) | |
| <8 | 0 |
| ≥8,<9 | 16 549 (85.9) |
| ≥9,<10 | 2321 (12.1) |
| ≥10 | 391 (2.0) |
| Comorbidities of interest, n (%) | |
| Hypertension | 2591 (13.5) |
| Type 2 diabetes | 983 (5.1) |
| Ischaemic heart disease | 356 (1.8) |
| Heart failure | 295 (1.5) |
| Cerebrovascular disease | 271 (1.4) |
| Hyperlipidaemia | 2212 (11.5) |
| Number of comorbidities, n (%) | |
| 0 | 13 796 (71.6) |
| 1 | 3380 (17.5) |
| 2 | 1214 (6.3) |
| 3 | 532 (2.8) |
| 4 | 228 (1.2) |
| 5 | 90 (0.5) |
| 6 | 19 (<0.1) |
| 7 | 2 (<0.1) |
| Concomitant medications, n (%) | |
| Antihyperlipidaemic drug | 1315 (6.8) |
| ACE inhibitor | 138 (0.7) |
| ARB | 1712 (8.9) |
| Diuretic drug | 385 (2.0) |
| Antidiabetic drug | 407 (2.1) |
*eGFR (male)=194 × sCr−1.094 × age−0.287, eGFR (female)=194 × sCr−1.094 × age−0.287 × 0.739.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; sUA, serum uric acid levels.